PCP Toxicity Clinical Presentation

  • Author: Stephan Brenner, MD, MPH; Chief Editor: Timothy E Corden, MD   more...
 
Updated: Mar 21, 2012
 

History

  • The dissociative effects of phenylcyclohexyl piperidine (PCP), also known as phencyclidine, cause patients to have disorganized thought processes, including delirium, amnesia, paranoia, and dysphoria. Therefore, obtaining a reliable history may not be possible.
  • In addition, because PCP is frequently adulterated, patients are unlikely to know that they have ingested PCP.
  • The patient's friends and family should be questioned, if possible, to gain a greater understanding of the situation.
Next

Physical

Diagnosis of PCP intoxication is generally made clinically. PCP exposure is suggested by the patient's fluctuating behavior, nystagmus, motor disturbances, and autonomic stimulation.

  • The presentation of patients with PCP intoxication widely varies from inebriated and calm to agitated and, in some cases, extremely violent. An important diagnostic clue is nystagmus (lateral, horizontal, or rotatory). A large case series demonstrated nystagmus in 57% of patients with PCP intoxication, although smaller studies have found an incidence of 85% or higher.[12] Many CNS depressants can produce nystagmus when taken in high doses; however, the patient is generally sedated when nystagmus is observed. In PCP exposure, the patient may have nystagmus when he or she is awake and agitated. Additional autonomic effects at low doses (less than 5 mg) include hypertension, tachycardia, tachypnea with shallow breathing, salivation, flushing, and diaphoresis.
  • Central and peripheral nervous system effects include generalized numbness of extremities, loss of muscular coordination, and mental status can vary from stimulation and euphoria to depression and coma, which occurs in a dose-related manner. At high doses (10 mg or more) blood pressure, heart rate and respirations may fall. This is often accompanied by nausea, vomiting, blurred vision, drooling, ataxia and dizziness.
    • Motor disturbances include dystonic reactions: opisthotonos, torticollis, tortipelvis, facial grimacing, myoclonic movements, tremor, hyperactivity, athetosis, stereotypies, and catalepsy. Patients may demonstrate bizarre posturing or facial expressions.
    • Psychobehavioral features of PCP intoxication often mimic symptoms of schizophrenia and can include delusions, hallucinations, acute anxiety, paranoia, disorganized thinking, violence, and a sensation of distance from one’s environment.[13] Elevation of anxious symptoms is frequently experienced. Long-term abuse of PCP may produce memory loss, speech difficulties, depression, and weight loss. Addiction to and withdrawal from PCP can occur after chronic use and manifest as craving and compulsive PCP-seeking behavior.[14]
    • During acute presentations in the emergency department PCP abusers may become violent or suicidal and should be seen as a danger to themselves and/or others. High doses of PCP can cause seizures, coma, hyperthermia and death (frequently related to unintentional injury or suicide while intoxicated). Coma is often related to substances like alcohol or benzodiazepines that can enhance the sedative effects of PCP.[15]
    • The evaluation of PCP-intoxicated patients with actual or suspected trauma may be challenging because of the dissociative anesthetic effects that can mask signs and symptoms (eg, abdominal pain or those associated with hidden injuries). Like ketamine, PCP is thought to prevent the integration of sensory input to create meaningful responses. Because of the analgesic effects of PCP and lack of normal pain response, PCP-intoxicated patients have sometimes been described as having extraordinary strength. PCP-intoxicated patients have broken handcuffs and fractured bones in the process.
    • Children may inhale PCP fumes in their environments, or they may ingest or have topical exposure to PCP in their surroundings. Most parents who accompany their children for treatment of PCP exposure deny the possibility of their child's drug intoxication. Children exposed to PCP typically have symptoms similar to those of adults and can exhibit diminished response to tactile and verbal stimuli, bizarre behavior, ataxia, nystagmus, expressionless stare, dystonic posturing, irritability, poor feeding, seizures, and possibly miosis and hypertension.[16]
  • Incidences of hallmark findings in 1000 patients with PCP intoxication are as follows:[9]
    • Nystagmus - 57.4%
    • Hypertension - 57%
  • Incidences of sensorium findings in 1000 patients with PCP intoxication are as follows:
    • Alert and oriented - 45.9%
    • Acute brain syndrome - 36.9%
    • Unconsciousness - 10.6%
    • Lethargy, stupor, or both - 6.6%
  • Incidences of behavioral findings in 1000 patients with PCP intoxication are as follows:
    • Violence - 35.4%
    • Agitation - 34%
    • Bizarreness - 28.8%
    • Hallucinations, delusions, or both - 18.5%
    • Muteness and stare - 11.7%
    • Nudism - 3.3%
    • None - 3.5%
  • Incidences of motor findings in 1000 patients with PCP intoxication are as follows:
    • Generalized rigidity - 5.2%
    • Grand mal seizures - 3.1%
    • Localized dystonias - 2.4%
    • Facial grimacing - 1.7%
    • Athetosis - 1.3%
  • Incidences of cholinergic findings in 1000 patients with PCP intoxication are as follows:
    • Diaphoresis - 3.9%
    • Bronchospasm - 2.1%
    • Pupils smaller than 1 mm - 2.1%
    • Hypersalivation - 1.7%
    • Bronchorrhea - 0.6%
  • Incidences of anticholinergic findings in 1000 patients with PCP intoxication are as follows:
    • Pupils larger than 4 mm - 6.2%
    • Urinary retention - 2.4%
  • Incidences of abnormal vital signs in 1000 patients with PCP intoxication are as follows:
    • Tachycardia - 30%
    • Hypothermia - 6.4%
    • Apnea - 2.8%
    • Hyperthermia - 2.6%
    • Cardiac arrest - 0.3%
    • Hypotension - 1.6%
  • Ketamine produces physical effects similar to PCP; however, symptoms are often of shorter duration. The hallmark of ketamine is its dissociative effect. Ketamine-provoked sensations are dose-related and range from a pleasant feeling of floating in a colorful “wonder world” (“K-land”) to the terrifying feeling of complete sensory detachment similar to a near-death or out of body experiences (“K-hole”).[17]
  • Other symptoms that can occur with ketamine intoxication include the following:[1]
    • Increased intracranial and intraocular pressures, decreased seizure threshold, dizziness
    • Neuromuscular disturbances, including muscle rigidity, slurred speech, blank stare, loss of coordination, numbness, polyneuropathy, diplopia, and nystagmus
    • Effects on the autonomic nervous system at low doses (eg, bronchodilation, hypersalivation, hyperthermia, elevated blood pressure and heart rate); respiratory and cardiac arrest (at high doses)
    • Psychobehavioral symptoms (eg, sense of invulnerability/exaggerated strength, aggressive/violent behavior, hallucinations, delirium, amnesia, depression, long-term memory loss, cognitive deficits); tolerance and dependence (with chronic use)
Previous
 
 
Contributor Information and Disclosures
Author

Stephan Brenner, MD, MPH  Resident Physician, Department of Emergency Medicine, Washington University in St Louis School of Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Bill Dribben, MD  Assistant Professor, Department of Emergency Medicine, Washington University School of Medicine

Bill Dribben, MD is a member of the following medical societies: American Academy of Emergency Medicine and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Halim Hennes, MD, MS  Division Director, Pediatric Emergency Medicine, University of Texas Southwestern Medical Center at Dallas, Southwestern Medical School; Director of Emergency Services, Children's Medical Center

Halim Hennes, MD, MS is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Jeffrey R Tucker, MD  Assistant Professor, Department of Pediatrics, Division of Emergency Medicine, University of Connecticut School of Medicine, Connecticut Children's Medical Center

Disclosure: Merck Salary Employment

Paul D Petry, DO, FACOP, FAAP  Consulting Staff, Freeman Pediatric Care, Freeman Health System

Paul D Petry, DO, FACOP, FAAP is a member of the following medical societies: American Academy of Osteopathy, American Academy of Pediatrics, American College of Osteopathic Pediatricians, and American Osteopathic Association

Disclosure: Nothing to disclose.

Chief Editor

Timothy E Corden, MD  Associate Professor of Pediatrics, Co-Director, Policy Core, Injury Research Center, Medical College of Wisconsin; Associate Director, PICU, Children's Hospital of Wisconsin

Timothy E Corden, MD is a member of the following medical societies: American Academy of Pediatrics, Phi Beta Kappa, Society of Critical Care Medicine, and Wisconsin Medical Society

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of eMedicine gratefully acknowledge the contributions of previous author Ryan J Petersen, MD, to the original writing and development of this article.

References
  1. Freese TE, Miotto K, Reback CJ. The effects and consequences of selected club drugs. Journal of Substance Abuse Treatment. J Subst Abuse Treat. September 2002;23(2):151-6. [Medline]. [Full Text].

  2. Smith KM, Larive LL, Romanelli F. Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. Am J Health-Syst Pharm. June 2002;59(11):1067-76. [Medline].

  3. Misra AL, Pontani RB, Bartolomeo J. Persistence of phencyclidine (PCP) and metabolites in brain and adipose tissue and implications for long-lasting behavioural effects. Res Commun Chem Pathol Pharmacol. Jun 1979;24(3):431-45. [Medline].

  4. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future national survey results on drug use, 1975-2006: Volume I, Secondary school students 2006. Bethesda, MD: National Institute on Drug Abuse; September 2007. [Full Text].

  5. Ball JK, Johnson E, Foley E. Drug Abuse Warning Network, 2005:National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: U.S. Department of Health and Human Services; February 2007. [Full Text].

  6. The DAWN Report: Club Drugs, 2002 Update. U.S. Department of Health and Human Services; July 2004. [Full Text].

  7. Mallonee E, Morin C, Ball J. Mortality Data from the Drug Abuse Warning Network, 2002. Rockville, MD: U.S Department of Health and Human Services; January 2004. [Full Text].

  8. Poklis A, Graham M, Maginn D, Branch CA, Gantner GE. Phencyclidine and violent deaths in St. Louis, Missouri: a survey of medical examiners' cases from 1977 through 1986. Am J Drug Alcohol Abuse. 1990;16(3-4):265-74. [Medline].

  9. McCarron MM, Schulze BW, Thompson GA. Acute phencyclidine intoxication: incidence of clinical findings in 1,000 cases. Ann Emerg Med. May 1981;10(5):237-42. [Medline].

  10. Akmal M, Valdin JR, McCarron MM. Rhabdomyolysis with and without acute renal failure in patients with phencyclidine intoxication. Am J Nephrol. 1981;1(2):91-6. [Medline].

  11. Schifano F, Corkery J, Oyefeso A, Tonia T, Ghodse AH. Trapped in the "K-hole": Overview of Deaths Associated With Ketamine Misuse in the UK (1993-2006). J Clin Psychopharmacol. February 2008;28(1):114-16. [Medline].

  12. Barton CH, Sterling ML, Vaziri ND. Phencyclidine intoxication: clinical experience in 27 cases confirmed by urine assay. Ann Emerg Med. May 1981;10(5):243-6. [Medline].

  13. Gonzalez-Maeso J, Sealfon SC. Psychedelics and schizophrenia. Trends Neurosci. Apr 2009;32(4):225-32. [Medline].

  14. Yago KB, Pitts FN Jr, Burgoyne RW, Aniline O, Yago LS, Pitts AF. The urban epidemic of phencyclidine (PCP) use: clinical and laboratory evidence from a public psychiatric hospital emergency service. J Clin Psychiatry. May 1981;42(5):193-6. [Medline].

  15. Hoaken PN, Stewart SH. Drugs of abuse and the elicitation of human aggressive behavior. Addict Behav. Dec 2003;28(9):1533-54. [Medline].

  16. Schwartz RH, Einhorn A. PCP intoxication in seven young children. Pediatr Emerg Care. Dec 1986;2(4):238-41. [Medline].

  17. Muetzelfeldt L, Kamboj SK, Rees H, Taylor J, Morgan CJ, Curran HV. Journey through the K-hole: phenomenological aspects of ketamine use. Drug Alcohol Depend. June 2008;95(3):219-29. [Medline].

  18. Piecuch S, Thomas U, Shah BR. Acute dystonic reactions that fail to respond to diphenhydramine: think of PCP. J Emerg Med. May-Jun 1999;17(3):379-81. [Medline].

  19. Work Group on Quality Issues. Bukstein OG. Practice parameter for the assessment and treatment of children and adolescents with substance use disorders. Washington, DC: American Academy of Child and Adolescent Psychiatry; 2004.

  20. Picchioni AL, Consroe PF. Activated charcoal--a phencyclidine antidote, or hog in dogs. N Engl J Med. Jan 25 1979;300(4):202. [Medline].

  21. Fauman B, Baker F, Coppleson LW. Psychosis-induced by phencyclidine. JACEP. 1975;4:223-5.

Previous
Next
 
Phenylcyclohexyl piperidine (PCP), also known as phencyclidine, in tablet form. Image courtesy of the US Drug Enforcement Administration.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.